ARWR * Stock Overview
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Arrowhead Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$586.00 |
| 52 Week High | US$619.39 |
| 52 Week Low | US$583.00 |
| Beta | 0.87 |
| 1 Month Change | 0% |
| 3 Month Change | 0.51% |
| 1 Year Change | -58.11% |
| 3 Year Change | -45.03% |
| 5 Year Change | n/a |
| Change since IPO | -41.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| ARWR * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | -58.1% | 0% | 0% |
Return vs Industry: ARWR * underperformed the MX Biotechs industry which returned -6% over the past year.
Return vs Market: ARWR * underperformed the MX Market which returned 3.7% over the past year.
Price Volatility
| ARWR * volatility | |
|---|---|
| ARWR * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: ARWR * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ARWR *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 397 | Chris Anzalone | arrowheadpharma.com |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets.
Arrowhead Pharmaceuticals, Inc. Fundamentals Summary
| ARWR * fundamental statistics | |
|---|---|
| Market cap | Mex$50.88b |
| Earnings (TTM) | -Mex$3.24b |
| Revenue (TTM) | Mex$4.59b |
11.1x
P/S Ratio-15.7x
P/E RatioIs ARWR * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARWR * income statement (TTM) | |
|---|---|
| Revenue | US$256.21m |
| Cost of Revenue | US$0 |
| Gross Profit | US$256.21m |
| Other Expenses | US$437.32m |
| Earnings | -US$181.11m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.69 |
| Gross Margin | 100.00% |
| Net Profit Margin | -70.69% |
| Debt/Equity Ratio | 68.9% |
How did ARWR * perform over the long term?
See historical performance and comparison